Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.29), $0.05 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $1.91 million versus the consensus estimate of $850.68 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.